Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Shares Slide 7.3 Percent on Wider Q4 Net Loss and Predictions of More Red in 06

NEW YORK, Feb. 23 (GenomeWeb News) - Cepheid shares were down 7.31 percent, or $.71, at $9 in afternoon trade after the company reported a wider fourth-quarter net loss and forecast deeper losses in 2006.


Cepheid yesterday reported a a net loss of $3.2 million, or $.08 per share during the third quarter, compared with a net loss of $3.0 million, or $.07 per share during the same quarter last year.


The company said fourth quarter revenues rose 16 percent to $23.6 million from $20.3 million year over year, driven by 15 percent growth in product sales.


The company attributed the increase primarily to a growth in product sales, including sales of reagents and disposables, which increased to $22.2 million from $19.4 million in the year-ago period.


R&D spending during the quarter rose to $5.2 million, compared to $4.4 million during the fourth quarter last year.


Cepheid expects a net loss in the range of $7 million to $9 million in 2006 on product sales in the range of $94 million to $98 million.


As of Sept. 30, 2005, Cepheid had $16.1 million in cash and cash equivalents and $21.2 million in marketable securities.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.